NAC for Mental Health: OCD, Addiction, and Depression

← Back to articles

N-acetylcysteine (NAC) is best known as the hospital antidote for acetaminophen overdose. Over the past two decades it has also become one of the more seriously studied over-the-counter agents in psychiatry, with controlled trials in obsessive-compulsive disorder (OCD), substance-use disorders, and depression. The honest summary up front: the mechanism is plausible, some trials are clearly positive, several well-conducted trials are clearly negative, and NAC is best understood as a low-risk adjunct under investigation — not an established treatment.

The Glutamate-Glutathione Connection

NAC acts through two relevant pathways. As a cysteine donor it replenishes glutathione, the body's principal intracellular antioxidant, which is depleted in several psychiatric conditions. More relevant to its behavioral effects, NAC drives the cystine-glutamate antiporter, which helps regulate extracellular glutamate tone in regions such as the nucleus accumbens and anterior cingulate. Because disrupted glutamate signaling is implicated in compulsive and addictive behavior, restoring it is the leading hypothesis for how NAC might help.

NAC for OCD

The OCD evidence is genuinely mixed, and that matters. A 2012 randomized, double-blind trial by Afshar and colleagues gave NAC up to 2,400 mg/day as an add-on to serotonin-reuptake inhibitors in 48 patients with treatment-refractory OCD; 52.6% of the NAC group were full responders (a 35% or greater reduction in Yale-Brown Obsessive Compulsive Scale, Y-BOCS, score) versus 15% on placebo.¹ A 2016 trial by Paydary and colleagues in moderate-to-severe OCD similarly found a significant advantage for NAC augmentation on Y-BOCS.² But the largest and longest single trial — Costa and colleagues, 2017, NAC 3,000 mg/day over 16 weeks in treatment-resistant OCD — found no significant difference from placebo on the primary outcome (the NAC group improved by 4.3 Y-BOCS points versus 3.0 on placebo; P = .92), with a hint of benefit only for anxiety.³ A 2024 systematic review and meta-analysis of six RCTs (195 patients) concluded that NAC augmentation may help moderate-to-severe OCD at five to eight weeks, but found no significant effect over shorter or longer windows and called for larger, longer trials.⁴ Promising, not proven.

NAC for Addiction and Compulsive Behaviors

The addiction literature shows the same split between encouraging early trials and sobering replications. In cannabis-dependent adolescents, Gray and colleagues (2012) found that NAC 1,200 mg twice daily roughly doubled the odds of a cannabis-negative urine test versus placebo (odds ratio 2.4).⁵ However, the larger ACCENT trial in 302 cannabis-dependent adults (2017) found NAC no better than placebo — abstinence rates were essentially identical (22.3% vs 22.4%).⁶ For cocaine dependence, a 111-person trial was negative overall, though it suggested NAC might help prevent relapse specifically in people who had already achieved abstinence.⁷ The clearest positive signal is in body-focused repetitive behaviors: Grant and colleagues (2009) found NAC markedly reduced hair-pulling in trichotillomania, with 56% "much or very much improved" versus 16% on placebo.⁸

Depression, Dosing, and Safety

For mood, the most cited trial is Berk and colleagues (2008): NAC 1,000 mg twice daily as an adjunct in bipolar disorder produced a significant improvement in depressive symptoms over 24 weeks (a roughly 8-point reduction on the Montgomery-Åsberg Depression Rating Scale), though the benefit faded after the drug was withdrawn and there was no effect on time to a new mood episode.⁹ A broad 2015 systematic review of NAC across psychiatry and neurology found favorable but still-preliminary evidence in several conditions, including bipolar depression, trichotillomania, and substance use, while explicitly cautioning that larger confirmatory trials are needed.¹⁰

Most psychiatric research uses 1,800–3,000 mg/day in divided doses. NAC is generally well tolerated; the most common complaints are gastrointestinal — nausea, heartburn, abdominal pain, and diarrhea — and tend to ease when it is taken with food. Because NAC can affect glutamate signaling and has mild antiplatelet activity, anyone taking it alongside psychiatric medication, anticoagulants, or nitroglycerin should clear it with the prescribing clinician first, and it is not a substitute for established treatment of any of these conditions.